{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T08:24:38Z","timestamp":1745569478833},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T00:00:00Z","timestamp":1316044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Palivizumab effectiveness data on respiratory syncytial virus (RSV) infections are limited to trial settings and vary considerably between selected high\u2010risk populations. This study aimed to evaluate effectiveness in a community\u2010based sample.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cohort study of children with \u22653\u2009months Florida Medicaid fee\u2010for\u2010service eligibility between 1998 and 2004 who also had matching birth certificates. Children entered the cohort at the beginning of the RSV season, after a minimum of 60\u2009days in ambulatory care, and were followed until the earliest of the following: season end, second birthday, loss of eligibility, hospitalization, or death. Study endpoint was the first RSV\u2010related hospitalization. To evaluate the presence of confounding, a second endpoint, hospitalizations for pneumonia or bronchiolitis secondary to specified bacterial or viral pathogens other than RSV, was used. Palivizumab exposure defined as first use (day 1\u201330 of first dose), subsequent use (days 1\u201330 of each subsequent dose), and former use (days 31\u201360 after any dose if delays or no readministration occurred) was compared with non\u2010use with a Cox regression model, adjusting for confounders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Hazard ratios (HRs) for RSV hospitalizations were 0.89 (95%CI, 0.71\u20131.12), 0.56 (95%CI, 0.46\u20130.69), and 0.71 (95%CI, 0.51\u20130.97) for first, subsequent, and former use, respectively. HRs for hospitalization because of non\u2010RSV infections were 1.31 (95%CI, 1.04\u20131.65), 1.03 (95%CI, 0.86\u20131.23), and 1.05 (95%CI, 0.78\u20131.41), indicating residual confounding for first but not for subsequent and former use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this community\u2010based study, palivizumab was associated with a reduction in severe RSV infections of a magnitude comparable to the lower clinical trial efficacy estimates. Protection appears to extend beyond the currently recommended monthly dosing schedule. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.2246","type":"journal-article","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T15:33:22Z","timestamp":1316100802000},"page":"53-60","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness of palivizumab prophylaxis in infants and children in Florida"],"prefix":"10.1002","volume":"21","author":[{"given":"Almut G.","family":"Winterstein","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy College of Pharmacy University of Florida  Gainesville FL USA"},{"name":"Department of Epidemiology Colleges of Medicine and Public Health &amp; Health Professions University of Florida  Gainesville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hampp","sequence":"additional","affiliation":[{"name":"Division of Epidemiology I, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa","family":"Saidi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine University of Florida  Gainesville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.3.531"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00454-2"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1754.2002.00057.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.6.1442"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2010.298"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-2345"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20507"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318157da9b"},{"issue":"12","key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.inf.0000145406.74341.c7","article-title":"Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia","volume":"23","author":"Grimaldi M","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000086403.50417.7c"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000090921.21313.d3"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200011000-00007"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318174e0c4"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.156.10.1034"},{"key":"e_1_2_8_16_1","first-page":"46","article-title":"A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis","volume":"16","author":"Frogel MP","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_8_17_1","unstructured":"Aetna Clinical Service Bulletin.Synagis (palivizumab) for prevention of respiratory syncytial virus (RSV) infections. Aetna Inc. December2010.http:\/\/www.aetna.com\/cpb\/medical\/data\/300_399\/0318.html[10 January 2011]."},{"key":"e_1_2_8_18_1","unstructured":"Florida RSV Surveillance Program Historical Trends. Florida Department of Health.http:\/\/www.doh.state.fl.us\/Disease_ctrl\/epi\/RSV\/rsv_trends.htm[16 December2009]."},{"key":"e_1_2_8_19_1","unstructured":"The National Respiratory and Enteric Virus Surveillance System (NREVSS).Centers for Disease Control and Prevention.http:\/\/www.cdc.gov\/surveillance\/nrevss\/rsv\/default.html[16 December2009]."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.12.016"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0226"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199809000-00007"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200206000-00020"},{"key":"e_1_2_8_24_1","unstructured":"HamppC.Utility of Current Surveillance Systems to Detect Respiratory Syncytial Virus Seasons and Implications for Immunoprophylaxis.Doctoral Dissertation.2009. University of Florida Gainesville FL."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2008.28"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199709000-00005"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2007.00034.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2008.01023.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000143647.88873.66"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2246","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.2246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:06:45Z","timestamp":1696853205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.2246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/pds.2246"],"URL":"https:\/\/doi.org\/10.1002\/pds.2246","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,15]]}}}